Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Subscriptions

Contact Info

Email Alert Service

Links

Evidence from Rheumatoid Arthritis Trials for Approval: What Does It Mean? With Special Reference to Using Radiographic Endpoints

KENT JOHNSON

ABSTRACT. Since medicine remains largely empirical, clinical knowledge about therapy is derived primarily from experiments designed to control confounders that use inferential techniques applied to the null hypothesis model. On a public health scale, health agencies need to assess the evidentiary weight supplied for new therapies to make approval decisions. In the field of rheumatoid arthritis (RA), there are additional analytic challenges such as designation of endpoints or missing data. The intellectual architecture that underpins these exercises continues to evolve, and recently the US Food and Drug Administration released an RA Guidance Document to describe some aspects of these exercises. This article focuses on the use of measurements of radiographic endpoints in particular as an element in the evidentiary portrayal of therapeutic efficacy in RA. (J Rheumatol 2000;27:549-51)

Key Indexing Terms:

RHEUMATOID ARTHRITIS
ENDPOINTS
TRIALS



Return to February 2000 Table of Contents



© 2000. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.